ADIL · ADIAL PHARMACEUTICALS, INC.

NasdaqHealthcareBiotechnology

Adial Pharmaceuticals Inc Is A Clinical-Stage Biopharmaceutical Company Focused On The Development Of Therapeutics For The Treatment Or Prevention Of Addiction And Related Disorders. Its Investigational New Drug Candidate, Ad04, Is Being Developed As A Therapeutic Agent For The Treatment Of Alcohol Use Disorder. The Company Operates As One Operating Segment With A Focus On Drug Development For Addiction And Related Disorders.

HealthcareNasdaqUSVery Low Float

$5.17

+126.8% latest move

Price & move as of the most recent catalyst (Jun 11) — not a live quote.

FLOAT

2.4M

FREE FLOAT %

92%

SHARES O/S

2.6M

MARKET CAP

$10.3M

EXCHANGE

Nasdaq

COUNTRY

ADIL Catalyst History

Corporate DealsAcquisition ClosedJun 11, 2026 · 11:44am ET

ADILADIAL PHARMACEUTICALS, INC.

Adial Pharmaceuticals Acquires Azora Therapeutics and Announces Private Placement

Transaction involves an all-stock acquisition and a concurrent private placement.

Be early on the next ADIL spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →

ADIL · ADIAL PHARMACEUTICALS, INC.

ADIL Catalyst History

Adial Pharmaceuticals Acquires Azora Therapeutics and Announces Private Placement

Adial Pharmaceuticals Acquires Azora Therapeutics and Announces Private Placement

Adial Pharmaceuticals Granted New U.S. Patent for Genetic-Based Treatment Method

Adial Pharmaceuticals Granted New U.S. Patent for Genetic-Based Treatment Method

Adial Pharmaceuticals Receives Positive FDA Feedback on AD04 Bridging Strategy

Adial Pharmaceuticals Receives Positive FDA Feedback on AD04 Bridging Strategy

Adial Pharmaceuticals Advances to Second Cohort in AD04 Pharmacokinetics Study

Adial Pharmaceuticals Advances to Second Cohort in AD04 Pharmacokinetics Study

Adial Pharmaceuticals Announces Publication of Positive AD04 Trial Data

Adial Pharmaceuticals Announces Publication of Positive AD04 Trial Data

Adial Pharmaceuticals Granted New Patent by USPTO

Adial Pharmaceuticals Granted New Patent by USPTO